BACKGROUND: This was an open-label, single-center study of the long-term efficacy and effectiveness of venlafaxine extended release (XR) in the treatment of chronic pain and depression in outpatients. All patients have been diagnosed with major depressive disorder (MDD) of various types, with or without chronic pain, and had previously failed treatment with either tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs). METHODS: Efficacy of treatment was determined using the 21-item Hamilton Rating Scale for Depression (HAMD-21), the Visual Analogue Scale (VAS) for the evaluation of pain, and a 12-item quality of life scale (QOL). Patients were treated in an unblended open trial for 1 year with 150 mg or more of venlafaxine XR once daily. RESULTS: After 1 year of treatment, 21-item Hamilton Rating Scale for Depression, Visual Analogue Scale, and quality of life scores were significantly improved from permanent baseline scores. CONCLUSION: These data show long-term efficacy and effectiveness of venlafaxine XR, a serotonin (5-HT) and norepinephrine (NE) and dopamine (DA) reuptake inhibitor antidepressant agent, having analgesic properties.
BACKGROUND: This was an open-label, single-center study of the long-term efficacy and effectiveness of venlafaxine extended release (XR) in the treatment of chronic pain and depression in outpatients. All patients have been diagnosed with major depressive disorder (MDD) of various types, with or without chronic pain, and had previously failed treatment with either tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs). METHODS: Efficacy of treatment was determined using the 21-item Hamilton Rating Scale for Depression (HAMD-21), the Visual Analogue Scale (VAS) for the evaluation of pain, and a 12-item quality of life scale (QOL). Patients were treated in an unblended open trial for 1 year with 150 mg or more of venlafaxine XR once daily. RESULTS: After 1 year of treatment, 21-item Hamilton Rating Scale for Depression, Visual Analogue Scale, and quality of life scores were significantly improved from permanent baseline scores. CONCLUSION: These data show long-term efficacy and effectiveness of venlafaxine XR, a serotonin (5-HT) and norepinephrine (NE) and dopamine (DA) reuptake inhibitor antidepressant agent, having analgesic properties.
Authors: Jordan F Karp; Bruce L Rollman; Charles F Reynolds; Jennifer Q Morse; Frank Lotrich; Sati Mazumdar; Natalia Morone; Debra K Weiner Journal: Pain Med Date: 2012-02-07 Impact factor: 3.750
Authors: Adam Yasgar; Silviya D Furdas; David J Maloney; Ajit Jadhav; Manfred Jung; Anton Simeonov Journal: PLoS One Date: 2012-09-20 Impact factor: 3.240
Authors: Bette Caan; Andrea Z LaCroix; Hadine Joffe; Katherine A Guthrie; Joseph C Larson; Janet S Carpenter; Lee S Cohen; Ellen W Freeman; JoAnn E Manson; Katherine Newton; Susan Reed; Kathy Rexrode; Jan Shifren; Barbara Sternfeld; Kris Ensrud Journal: Menopause Date: 2015-06 Impact factor: 3.310
Authors: Eric W de Heer; Jack Dekker; Jonna F van Eck van der Sluijs; Aartjan Tf Beekman; Harm Wj van Marwijk; Tjalling J Holwerda; Pierre M Bet; Joost Roth; Leona Hakkaart-Van Roijen; Lianne Ringoir; Fiona Kat; Christina M van der Feltz-Cornelis Journal: BMC Psychiatry Date: 2013-05-24 Impact factor: 3.630